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Abstract
Attention has heightened over the last several years to the importance of managing pain,
agitation, and delirium in mechanically ventilated patients due to the multiple long‐
term adverse effects patients experience after an intensive care unit (ICU) admission.
Furthermore, clinical practice is being molded not just by the guidelines and random‐
ized controlled trials, but also by the information gathered from real patient experiences
to improve care at the bedside. The literature continues to remain sparse for providing
guidance specifically in the oncology population. Therefore, several resources have been
combined to better assist clinicians on making sound decisions for keeping patients
comfortable on the ventilator while recognizing the differences in treatment that may
need to be employed due to these patients’ medical condition.
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1. Introduction
One of the leading causes of an intensive care unit (ICU) admission is acute respiratory failure
where approximately 44–69% of patients with malignancies requiring mechanical ventilation
due to the progression of cancer or chemotherapy toxicity [1]. Improved survival of critically
ill oncology patients has been due to the advances in the treatment of malignancies and more
appropriate triage of patients for ICU admission [2]. Thus, not all families of intubated patients
are met with discussions for end of life or hospice care of their loved one. Goals of weaning
and extubation to allow the resumption of cancer treatment have become more common.
There is a potential increase in number of oncology patients that clinicians will manage on
mechanical ventilation in the future. Therefore, the need for appropriate protocols to treat pain,
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agitation, and delirium is especially crucial for a population on chronic pain and anxiety
medications prior to admission. However, national guidelines published by the Society of
Critical Care Medicine (SCCM) in 2013 were primarily based on data from the nononcology
population, which poses challenges in applying such concepts to these patients. Such protocol
outcomes lack support from clinical trials in oncology patients. Studies involving ICU patients
with cancer have largely focused on mortality outcomes, rather than improvement of care, due
to these patients’ overall poor prognosis. Thus, the concepts described in the SCCM guidelines
must be applied simultaneously with literature on effective treatment of pain and agitation in
noncritically ill oncology patients.
In addition to clinical trials, patient interviews conducted in the ICU are gaining more attention
to help the clinician better predict the needs of the patient on mechanical ventilation. A
prospective study, conducted in a medical ICU, evaluated the symptom experience of patients
with a present or past diagnosis of cancer admitted during an 8‐month period. The patients
expressed the procedures associated with the greatest pain or discomfort were endotracheal
suctioning, endotracheal and nasogastric tubes, mechanical ventilation, arterial puncture, and
turning. The aspects of the environment reported to be most stressful were inability to
communicate, communicate, sleep disturbances, and limited family visitation hours [2]. In this
study, patients still experienced significant discomfort despite liberal administration of opioids
and sedatives, along with the implementation of palliative care recommendations. This could
be explained by the challenge of accurately assessing pain in mechanically ventilated patients,
as well as the rate in which patients felt their stress was not relived by medications. For these
reasons, it is imperative that a multidisciplinary team acquires a consistent and universal
method by which these patients’ pain, agitation, and delirium are managed. More importantly,
the clinicians should have a strong understanding of the pharmacology of opioids and
sedatives to ensure the safest agents are chosen.
2. Pain
The prevalence of pain has not been shown to differ between patients actively receiving
anticancer treatment and those with an advanced‐ or terminal‐phase disease. Studies have also
published that on average 56–82.3% of cancer patients’ pain is not adequately treated [3]. This
emphasizes the importance of performing accurate and timely assessments of pain to ensure
appropriate treatment. As recommended by SCCM guidelines, the gold standards for pain
assessments in ICU patients are the numerical rating scale or visual analog scale (VAS) if a
patient is communicative enough to express their level of pain. In some instances, such
assessments can be challenging in ICU patients receiving high‐dose sedatives during mechan‐
ical ventilation or those with altered level of consciousness [4]. If the patient is unable to self‐
report his/her pain, then the most valid and reliable assessments for pain are the behavioral
pain scale (BPS) and the critical pain observation tool (CPOT) outlined in Tables 1 and 2 [5],
which are consistent with recommendations by NCCN guidelines for adult cancer pain. Vital
signs alone are no longer recommended for detecting symptoms of pain. They only should be
used as a cue to perform further assessments [4].
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Indicator Descriptor Score
Facial expression No muscular tension observed Relaxed, neutral 0
Presence of frowning, brow lowering, orbit
tightening, and levator contraction
Tensed 1
All of the above facial movements plus eyelid tightly
closed
Grimacing 2
Body movements Does not move at all (does not necessarily mean
absence of pain)
The absence of
movements
0
Slow, cautious movements, touching or rubbing the
pain site, seeking attention through movements
Protection 1
Pulling tube, attempting to sit up, moving limbs/
thrashing, not following commands, striking at staff,
trying to climb out of bed
Restlessness 2
Muscle tension evaluation by
passive flexion and extension of
upper extremities
No resistance to passive movements Relaxed 0
Resistance to passive movements Tense, rigid 1
Strong resistance to passive movements, inability to
complete them
Very tense or rigid 2
Compliance with the ventilator
(intubated patients)
OR
Alarms not activated, easy ventilation Tolerating ventilator or
movement
0
Alarms stop spontaneously Coughing but tolerating 1
Asynchrony: blocking ventilation, alarms frequently
activated
Fighting ventilator 2
Vocalization (extubated patients) Talking in normal tone
or no sound
Talking in normal tone
or no sound
0
Sighing, moaning Sighing, moaning 1
Crying out, sobbing Crying out, sobbing 2
Table 1. Critical pain observation tool (CPOT) [5].
Chronic pain affects greater than 60% of oncology patients, with upwards of 66% experiencing
failure of therapy [6]. Subsequently, the majority of these patients are opioid tolerant and on
high doses of narcotics prior to being admitted. Upon ICU admission, many patients do not
have oral access or have multisystem failure that can preclude them from receiving specific
types of opioids. It becomes imperative that thorough medication reconciliations are per‐
formed to determine the amount of daily opioids the patient takes at home so that they can be
converted to the most appropriate and safest formulation in the ICU. When performing such
conversions, clinicians must consider incomplete cross tolerance if the patient is placed on an
opioid they are not receiving prior to admission. Long‐term exposure to one drug can result
in the development of tolerance to those with similar structures. However, this tolerance is
rarely complete with agents that bind to different receptors, thus the analgesic effect of the
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new agent is enhanced in the patient. Without appropriate conversions, the patient is at risk
of withdrawal or overdose when rotating opioids. However, the heightened analgesic effect
due to incomplete cross tolerance can also lead to excessive side effects such as respiratory
depression, nausea, sedation, and dysphoria [7]. The total daily dose of the patient's regimen,
both IV and oral, should be converted to the opioid to be initiated in the ICU using Table 3
and reduced by 20–30% for cross intolerance. Persistent or chronic pain should be controlled
using a combination of long‐acting agents, either extended or sustained release oral formula‐
tions or continuous IV infusions, in conjunction with short‐acting agent. Long‐acting opioid
typically comprises 50% of the total daily requirement [11].
Item Description Score
Facial expression Relaxed 1
Partially tightened (e.g., brow lowering) 2
Fully tightened (e.g., eyelid closing) 3
Grimacing 4
Upper limb movements No movement 1
Partially bent 2
Fully bent with finger flexion 3
Permanently retracted 4
Compliance with mechanical ventilation Tolerating movement 1
Coughing but tolerating ventilation for most of the time 2
Fighting ventilator 3
Unable to control ventilation 4
Table 2. Behavioral pain scale (BPS) [5].
Society of Critical Care Medicine Guidelines emphasize that many sources of pain have been
identified in ICU patients related to not only surgery, trauma, burns, or cancer but also
procedures. In a comparative, descriptive study, data were obtained from over 6000 patients
to describe pain intensity and procedural distress. Procedures were defined as wound dressing
changes, turning, tracheal suctioning, and wound drainage removal. The average pain score
was 5–7, and the most distressful procedures were turning and wound care. Unfortunately,
less than 20% of these patients actually received opiates before the procedures. With proce‐
dures performed so frequently in the ICU, this remains one of the areas that is poorly managed
[12]. Therefore, it is highly encouraged patients are pre‐treated with bolus doses of opioids.
Unrelieved pain leads to long‐term negative outcomes, such as patients recalling traumatic
memories of pain during their ICU admission. It has also been shown that inadequately treated
pain is associated with physiological consequences such as increase in catecholamines leading
to arteriolar vasoconstriction, impaired tissue perfusion, catabolic hypermetabolism resulting
in hyperglycemia, lipolysis, and breakdown of muscle [4].
Oncology Critical Care162
Drug Oral (mg) Parenteral (mg)
Morphine 30 10
Codeine 200 100
Oxycodone 20 n/a
Hydrocodone  30 n/a
Hydromorphone 7.5 1.5
Fentanyl n/a 0.1
Methadone Use ratio of 3:1 (morphine/methadone) to convert methadone to morphine
equivalents and then convert to desired opioid
Tramadol 120 100
Table 3. Opioid equianalgesic doses [8–10].
Managing pain in ICU patients, especially the mechanically ventilated, is almost always in
conjunction with managing agitation and delirium. Therefore, pain can be managed more
effectively and appropriately with several simple concepts employed:
1. Nurses should perform consistent and accurate pain assessments using the tools validated
in ICU patients with reassessments performed after analgesics are administered to
evaluate response to therapy.
2. Intermittent boluses versus continuous IV infusion strategies should be selected based on
the frequency and severity of pain and/or patient's mental status. The use of patient‐
controlled administration (PCA) should be highly considered for patients responsive and
cognitive to control delivery of boluses.
3. The type of opioid selected for each patient should be based on the drug pharmacokinetics/
pharmacodynamics including any risks for altered clearance if the patient has evidence
of organ dysfunction (see Tables 4 and 5).
4. Oral formulations should be limited to those patients with adequate gastrointestinal
absorption.
5. Regional or neuraxial (spinal or epidural) modalities can be considered for postoperative
analgesia.
6. Administer analgesics pre‐emptively prior to procedures (i.e., chest tube removal, line
insertion, turning the patient).
7. Analgesic agents should be started prior to sedative agents if there is any suspicion of
pain. After sedatives are initiated, pain assessments can be harder to perform and less
accurate in ensuring the patient is comfortable.
8. Pain medications should be titrated upward by 10–25% and doses selected based on the
pain assessments using nursing driven scales. Opioid rotation should be considered if
pain is inadequately controlled or persistent adverse effects are experienced [11].
9. Use of nursing‐driven protocol with effective multidisciplinary discussions for adjust‐
ment of such medication orders should occur on a routine basis.
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Analgesic Onset
(IV)
Duration
of action
t½ Dosing1 Common toxicities/major precautions
Fentanyl IV 1–2 min 0.1–5 h 1.5–
6 h
25–100 mcg every
15 min PRN pain
Infusion: 25–500
mcg/h
Large volume of distribution and high
lipophilicity increasing risk of accumulation in
tissues and sedation with prolonged infusions;
less hypotension effect than morphine;
accumulation with hepatic failure; rare: chest
wall rigidity at high doses serotonin syndrome
Hydromorphone
IV
5–15
min 
4–5 h 2–3 h 0.2–0.6 mg every
15 min PRN pain
Infusion:
0.5–5 mg/h
Alternative to fentanyl and morphine if long‐
acting agent is needed; accumulation in
hepatic failure
Morphine IV 5–10
min 
3–6 h 3–7 h 2–4 mg PRN pain
Infusion: 2–15
mg/h
Common: bradycardia/hypotension,
respiratory
depression, and sedation especially at higher
doses. Caution with risk of bronchospasm,
histamine release, accumulation of active
metabolite (3‐morphine glucuronide) in renal
failure that can lead to seizures
Methadone oral 1–3
days 
4–6 h 8–59 h 2.5–10 mg every
8–12 h (titrated
slowly every 3–5
days)
Common: prolongation of QTc, sedation
Caution with multiple drug interactions;
unpredictable pharmacokinetic/
pharmacodynamics; hepatic and renal failure
will delay clearance. Rare: serotonin syndrome
Tramadol (for
polyneuropathies
as second‐line
agent in patients
who did not
respond to
opioids)
1 h 9 h 6–8 h 50 mg once or twice
daily titrated to max
of 400 mg/day
Common: somnolence, constipation, dizziness,
and hypotension. Reduce dose in renal or
hepatic
dysfunction; precipitates seizures in patients
with history of seizures or those receiving
medications that reduce seizure threshold;
may increase risk of serotonin syndrome
with SSRIs and SNRIs
1More aggressive dosing recommendations based on higher tolerance to opioids in most cancer patients. More
conservative dosing is recommended for opioid‐naïve patients.
PRN, as needed; t½, half‐life of elimination; SSRIs, selective serotonin reuptake inhibitors; SNRIs, serotonin and
norepinephrine reuptake inhibitors; IV, intravenous; QTc, corrected QT interval.
Table 4. Comparison of most common opioids used in oncology ICU mechanically ventilated patients [4, 13–19].
2.1. Route of administration/formulation
The route of administration preferred for non‐ICU patients is often oral, whereas for critically
ill patients, intravenous is optimal when there is known or suspected altered gastrointestinal
(GI) tract absorption. Furthermore, other routes such as intramuscular (IM), subcutaneous, or
transdermal requiring systemic absorption are frequently avoided in critically ill patients due
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to erratic and unpredictable absorption [13]. Risks of changes in perfusion due to hemody‐
namic instability and fluid shifts can lead to potentiated or subtherapeutic effects.
2.2. Pharmacokinetic/pharmacodynamic properties and side effect profile
Table 4 illustrates the comparison of the most common analgesics used in ICU mechanically
ventilated patients, with the exception of meperidine, which is discouraged in an ICU setting
due to the high risk of neurotoxicity. Methadone is occasionally avoided due to the risk of QT
prolongation, interaction with common ICU medications, and difficulty dosing. In the
oncology setting, patients taking methadone at home can be encountered, and due to its
multiple side effects, it should be converted to alternative opioids if the patient is unstable or
lacks oral access. Methadone should not be discontinued abruptly without adequate alterna‐
tive opioids initiated as replacement therapy to prevent withdrawal.
When the patient is hemodynamically unstable or has renal insufficiency, then fentanyl or
hydromorphone is recommended as first line agents. Either of two agents, in addition to
morphine, can be used for patients with no renal insufficiency or those who are stable [24].
Clinicians should also be cognitive of possible inadequate metabolism and/or clearance of
medications in patients with renal and hepatic cancers which may not be evident by laboratory
values.
2.3. Nonopioid analgesics
Opioid analgesics are most often the first line agents employed in general ICU patients with
the ease of administration and ability to titrate. However, in patients with cancer, nonopioid
agents provide a novel approach to better controlling their pain long term and helping to
reduce opioid requirements. The WHO analgesic ladder provides guidelines for the treatment
of cancer pain by suggesting a sequential three step approach based on severity of pain.
Nonopioids are recommended for mild pain, weak opioids for moderate pain, and strong
opioids for severe pain with fixed scheduled dosing according to the pharmacokinetic
properties of the drugs. Typically, the nonopioids initiated in step 1 should be continued in
conjunction with opioids added in the next step to allow for agents with different mechanisms
of actions to improve analgesic control. There are several common nonopioid agents used to
treat cancer pain that can be continued in an ICU if the patient has appropriate access. Table 5
compares the various classes of nonopioid agents and pharmacokinetics as well as common
toxicities of which to be aware when using such agents in the ICU setting. Other nonopioids
found to effective in the oncology population are bisphosphonates for bone metastases and
medicinal cannabinoids that are not encouraged in the ICU due to their unsafe profile.
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Drug/Class Onset
of
action
t½ Dosing Place in therapy Common toxicities/major
precautions
APAP IV 5–10
min
2.4 h 650 mg q4 h‐
1000 mg IV q 6 h
(max 4 gm/day)
Opioid sparing effect.
IV is a suitable agent
for the treatment of
mild to moderate
pain in patients
with no oral access
or to assist with
reaching peak levels
with the first dose
faster
Adjust dose with CrCl <30
mL/min or with CRRT
APAP PO 30–60
min
2 h 325–1000 mg q4–6
h (max 4 gm/day)
Risk for hepatotoxicity; use
lower doses in older adults,
heavy alcohol use or those
who are malnourished
Ketorolac (IM/IV) 10 min 2.4–
8.6 h
30 mg IM/IV, then
15–20 mg IM or IV
q6 h up to 5 days
(max 120 mg/day 
× 5 days)
Ketorolac for acute
pain postsurgery
Benefit has been
shown when added
to an opioid in
WHO Step 3 More
effective for cancer
pain associated with
inflammation
Avoid in renal failure, GI
bleeding, platelet abnormality,
concomitant angiotensin
converting enzyme inhibitory
therapy, congestive heart
failure; risk of drug
interactions with
anticoagulants and
corticosteroids
Ibuprofen (PO) 25 min 1.8–
2.5 h
400 mg q4 h (max
2.4 gm/day)
Ketamine 30–40
sec
2–3 h Loading dose: 0.1–
0.5 mg/kg
Maintenance dose:
0.05–0.4 mg/kg/h
May decrease doses
of concurrently
used opioids;
provides analgesia
and sedation
as a “dissociative
anesthetic”; the
treatment of chronic
cancer pain not
controlled by
opioids or opioids
plus adjuvant analgesics
Mild to severe emergence
reactions (e.g., confusion,
excitement, irrational
behavior, hallucinations,
delirium) [rare];
hypertension; arrhythmias
Steroids N/A N/A Dexamethasone
2–8 mg oral, IV, or
Useful at any step in
the WHO analgesic
Gastrointestinal bleeding;
increase risk of infection;
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Drug/Class Onset
of
action
t½ Dosing Place in therapy Common toxicities/major
precautions
*Dexamethasone
most often
prescribed because
it causes less fluid
retention due to its
lower
mineralocorticoid
effect
SQ q8 h Prednisone
7.5–10 mg daily
ladder when pain is
due to edema or
inflammation such
as metastatic bone
pain, neuropathic,
and visceral pain
increased blood pressure;
metabolic abnormalities;
psychiatric disturbances;
increased appetite, weight
gain; insomnia
Regimens should be
tapered rather than
abruptly discontinued
if therapy exceeds
2 weeks
Gabapentin (PO) N/A 5–7 h Starting dose=100
mgTID 900–3600
mg/day in three
divided doses
Neuropathic pain CNS depression (common);
confusion; ataxia; adjust dose
in renal impairment; abrupt
discontinuation associated
with drug withdrawal
syndrome; seizures; adjust for
renal impairment
Carbamazepine
(PO)
4–5 h 26–65
h,
then
12–17
h
Starting dose = 50–
100 mg BID; 100–200
mg q4–6 h (max 1200
mg/day)
Neuropathic pain Somnolence (common);
nystagmus; lethargy; Stevens‐
Johnson syndrome (rare); toxic
epidermal necrolysis;
agranulocytosis; adjust for
CrCl <10 or hemodialysis;
caution with hepatic
impairment
PO, by mouth; IM, intramuscular; IV, intravenous; CrCl, creatinine clearance; BID, twice daily; TID, three times daily;
APAP, acetaminophen; t½, half‐life of elimination; SQ, subcutaneous; CRRT, continuous renal replacement therapy; q,
every; N/A, non‐applicable; GI, gastrointestinal; CNS, central nervous system.
Table 5. Comparison of major non‐opioid analgesic classes [4,20–23].
2.4. Unconventional modes of administration
Breathlessness is often a distressing symptom in oncology patients especially during end of
life. Alternative routes of opioid administration, via inhaled nebulization and intranasal, have
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been studied. Unfortunately, data are still lacking on the efficacy of such routes of adminis‐
tration. However, benefit has been seen due to the short onset of action with these modes of
delivery. Both morphine and fentanyl have been administered through nebulization, and
fentanyl is preferred intranasally due its lipophilic properties allowing for better absorption
[21].
2.5. Protocolized management of pain
In mechanically ventilated patients, use of protocols can greatly reduce the delay in treating
pain, ICU length of stay, high dose analgesics, and duration of mechanical ventilation. It is
advised to initiate orders that allow nurses to select the appropriate dose of an analgesic agent
based on the pain scale score. Minimal data exist on the incremental doses that should be
administered with various pain scores. However, orders for the analgesic agent of choice have
been applied to our current practice in an oncology ICU and proven to be effective which are
listed as follows:
• Fentanyl 25 mcg IV every 15 min as needed for numeric pain score 1–2, critical pain
observation tool (CPOT) 0–2, and/or Richmond agitation‐sedation scale (RASS) +1.
• Fentanyl 50 mcg IV every 15 min as needed for numeric pain score 3–4, CPOT 3–4, and/or
RASS +2.
• Fentanyl 75 mcg IV every 15 min as needed for numeric pain score 5–7, CPOT 5–6, and/or
RASS +3.
• Fentanyl 100 mcg IV every 15 min as needed for numeric pain score 8–10, CPOT 7–8,
and/or RASS +4.
Initial doses are defaulted but can be changed by the prescriber if more aggressive or more
conservative doses are needed.
Pain should be assessed routinely especially after analgesic agents are administered. Most
nursing standards expect pain to be reassessed within 15–30 min after treatment, and thus, the
frequency of analgesic medications should be written to allow redosing in a timely manner if
needed [4].
3. Analgesia-First Sedation
Recent literature now emphasizes the importance of adequately treating pain prior to use of
sedatives. The most common source of agitation identified in intubated patients is pain. If
agitation is treated immediately with sedatives, then the patient is at risk of experiencing the
physiologic consequences previously discussed because pain remains untreated. Therefore, it
may be beneficial to have intermittent analgesic medication orders written to PRN RASS scores
in addition to incremental pain scores to allow the nurse to adequately use such medications
for agitation (as shown in example above).
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If pain is ruled out as the cause of agitation, then other causes should be promptly considered
such as hypoxemia, hypoglycemia, hypotension, or withdrawal from alcohol or other drugs
[4]. Aside from treating such underlying causes, strategies should be used to help reduce
agitation by maintaining comfort for the patient, frequent reorientation, and optimization of
the environment to maintain normal sleep patterns. After addressing such issues, sedatives
only then should be considered if the patient remains agitated with a goal sedation level
established: light for goals of extubation (i.e. the patient is alert, calm, arousable, and able to
follow commands) or deep sedation with goals of synchronization with the ventilator, or the
prevention of movement in severe trauma/burns/paralysis (i.e. patient is unresponsive to
painful stimuli, unable to follow commands) with goals of synchronization with the ventilator,
or the prevention of movement severe trauma/burns). Most patients should have goals of light
sedation as many studies have demonstrated increased ICU length of stay, mechanical
ventilation, delirium, and muscle deconditioning with deep, prolonged sedation [25–27].
Agitation should be assessed as frequently as pain is assessed using the RASS or SAS scales
(Tables 6 and 7). Recommendations for options to treat agitation are in Table 8.
Scale  Label Description
+4 Combative Combative, violent
+3 Very agitated Pulls to remove tubes or catheters; aggressive
+2 Agitated Frequent nonpurposeful movement, fights ventilator
+1 Restless Anxious, apprehensive, movements not aggressive
0 Alert and calm Spontaneously pays attention to caregiver
−1 Drowsy Not fully alert, but has sustained awakening to voice (eye opening & contact >10 s)
−2 Light sedation Briefly awakens to voice (eyes open & contact < 10 s)
−3 Moderate sedation Movement or eye opening to voice (no eye contact)
−4 Deep sedation No response to voice, but movement or eye opening to physical stimulation
−5 Unarousable No response to voice or physical stimulation
Table 6. Richmond agitation sedation scale (RASS) [28].
Score Term Descriptor
7 Dangerous 
agitation
Pulling at ET tube, trying to remove catheters, climbing over bedrail, striking at staff, thrashing
side to side
6 Very
agitated
Requiring restraint and frequent verbal reminding of limits, biting ET tube
5 Agitated Anxious or physically agitated, calms to verbal instructions
4 Calm and
cooperative
Calm, easily arousable, follows commands
3 Sedated Difficult to arouse but awakens to verbal stimuli or gentle shaking, follow simple commands but
drifts off again
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Score Term Descriptor
2 Very
sedated
Arouses to physical stimuli but does not communicate or follow commands, may move
spontaneously
1 Unarous
able
Minimal or no response to noxious stimuli, does not communicate or follow commands
ET, endotracheal.
Table 7. Sedation agitation scale [29].
Drug/MOA Onset
of
action
t½ Effects Dosing Place in therapy Common toxicities/major
precautions
Dexmedeto‐
midine
Selective α2‐
agonist
5–10
min
1.8–
3.1
h
Anxiolytic,
sedative,
analgesic/
opioid
sparing
Bolus:
1 mcg/kg
over 10
min.
Infusion:
0.2–0.7
mcg/kg/h
Assists in keeping
patient calm and
arousable to wean
off the ventilator or
for the treatment
of acute hyperactive
delirium; causes
minimal respiratory
depression
Common: bradycardia
and hypotension,
hypertension with
loading dose.
Rare: loss of
airway reflexes, risk
for withdrawal after
prolonged (7
days) use. Infusion
must be tapered
slowly to prevent
rebound agitation;
slower emergence with
hepatic failure
Propofol
Binds to
GABAA,
glycine,
nicotinic,
and M1
muscarinic
receptors
1–2
min
26–
32 h
Sedative,
hypnotic,
anxiolytic,
amnestic,
antiemetic,
anticonvulsant
Bolus: 5
mcg/kg/
min
Infusion:
5–50
mcg/kg/
min
Light or heavy
sedation; ideal for
neurosurgery
patients
to allow for daily
neurological
assessments
or medical ICU
patients
requiring deep
sedation for vent
synchronization;
treatment of
seizures and
elevated intracranial
pressure
Hypotension; respiratory
depression;
hypertriglyceridemia
(with prolonged use),
rhabdomyolysis (rare),
pancreatitis (rare),
deep sedation with
propofol is associated
with longer emergence
times; lipid emulsion
delivering 1.1 kcal/mL
Midazolam
Activate γ‐
aminobutyric
acid A
(GABAA)
neuronal
receptors
2–5
min
3–11
h
Sedative,
hypnotic,
anxiolytic,
amnestic,
antiemetic,
anticonvulsant
1–14 mg/h
(max ∼0.1
mg/kg/h)
Patients requiring
deep sedation;
treatment of
seizures or
alcohol
withdrawal
Respiratory depression;
hypotension; accumulates
in hepatic dysfunction;
active metabolite
accumulates in renal
dysfunction; drug
has potential to
accumulate in adipose
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Drug/MOA Onset
of
action
t½ Effects Dosing Place in therapy Common toxicities/major
precautions
tissue with continuous
infusions
Lorazepam
Activate γ‐
aminobutyric
acid A (GABA
A) neuronal
receptors
15–20
min
8‐15
h
Sedative,
hypnotic,
anxiolytic,
amnestic,
antiemetic,
anticonvulsant
1–10 mg/h Patients requiring
deep sedation;
treatment of
seizures or
alcohol withdrawal
Respiratory depression;
hypotension; propylene glycol‐
related acidosis (rare);
nephrotoxicity evident by an
osmolar gap greater than 10–12
mOsm/L; accumulates in
hepatic dysfunction;
emergence from lorazepam
after prolonged infusions will
be longer than midazolam due
to its greater potency and
slower clearance; drug has
potential to accumulate in
adipose tissue with continuous
infusions
t½, half‐life of elimination; MOA, mechanism of action.
Table 8. Sedative agents [4,23,30].
4. Delirium
Delirium is defined as a syndrome with acute onset of cerebral dysfunction due to a change
or fluctuation in baseline mental status, inattention, or disorganized thinking [4]. Two forms
of delirium can exist: hyperactive (agitated, associated with hallucinations or delusions) or
hypoactive (calm, lethargic, confused, and sedated). With delirium now being shown to be a
strong predictor of negative long‐term outcomes, it is imperative that regular assessments are
performed to identify incidences of delirium and implementing preventative measures [24,31].
Such strategies include early mobilization, maintenance of light sedation while avoiding
benzodiazepines in those with underlying risk factors for delirium, promoting sleep in adult
ICU patients by optimizing environmental factors such as light, noise, clustering patient care
activities, and decreasing stimuli at night.
Medication‐induced delirium is not well studied and the exact onset, duration, or severity has
yet to be confirmed. Delirium is multifactorial and, therefore, medications should not be solely
considered as the cause in a patient experiencing changes in mental status. Most common
causes of delirium are in Table 9. Benzodiazepines have been studied extensively as a possible
risk factor for delirium. The data concerning benzodiazepines and outcomes with causing
delirium remain controversial. The MENDS and SEDCOM studies had similar results showing
higher delirium free days with or without coma when dexmedetomidine was administered
compared to midazolam or lorazepam. Furthermore, both have similar results in showing no
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difference in mortality and the length of ICU stay [33,34]. However, another meta‐analysis
including six trials comparing benzodiazepine versus nonbenzodiazepine sedatives found
opposite results. The ICU length of stay and duration of mechanical ventilation were signifi‐
cantly higher in the benzodiazepine group with no difference found in delirium prevalence or
all‐cause mortality [35]. Until further research can clarify such effects, caution is still warranted
when using these sedatives and other risk factors shown in Table 10 should be considered as
well.
Iatrogenic Exposure to sedative and opioid medications
Environmental Prolonged physical restraints
Immobilization
Disorientation to time and space
Other Drug or alcohol withdrawal
Sepsis
Medication induced Anticholinergics
Benzodiazepines
Opiates
Antipsychotics
Antispasmodics
Anticonvulsants
Corticosteroids
Table 9. Common causes of delirium [4,32].
Age
Pre‐existing delirium
History of baseline hypertension
Sedative‐associated coma
Mechanical ventilation
Polytrauma
Emergency surgery prior to ICU admission
APACHE II score
Metabolic acidosis
Delirium on the previous day
Table 10. Risk factors for delirium [36].
Two scales for assessing delirium with the highest psychometric (e.g., validity and reliability)
scores are the CAM‐ICU and the ICDSC [37]. Delirium should be assessed every 8–12 hours,
only after sedatives are decreased or interrupted and preferably during daytime hours.
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Drug Usual starting dose/
available
formulations 
Short-term adverse effects  Additional
 considerationsLow risk Moderate to high risk
Olanzapine  5 mg (PO,
disintegrating tablet,
IM)
EPS, NMS Anticholinergic,
weight gain,
dyslipidemia
Increased risk of accumulation
in elderly, female, and hepatic/
renal impairment; QT
prolongation
Quetiapine  12.5–25 mg (PO) NMS, weight gain,
tardive dyskinesia,
seizures, EPS
Anticholinergic (dry
mouth, constipation),
sedation, dizziness,
Hypotension (with rapid
titration), weight gain,
dyslipidemia
Associated with lowest risk of
EPS and tardive dyskinesia
Risperidone 0.5–1 mg (PO,
disintegrating tablet)
Anticholinergic, NMS,
cardiac conduction
abnormalities
Orthostatic hypotension
(with rapid titration),
EPS associated with doses >6
mg/day
Ziprasidone 20 mg PO 10 mg IM Anticholinergic,
sedation, EPS, NMS
QTc prolongation IM formulation contains a
nephrotoxin called
cyclodextrin that can
accumulate in renal
impairment; reduce dose in
hepatic impairment
PO, by mouth; IM, intramuscular; EPS, extrapyramidal symptoms; NMS, neuroleptic malignant syndrome.
Table 11. Atypical antipsychotics for the treatment of delirium [24,30,38,39].
Treatment of delirium should be directed at the probable underlying causes (e.g., alcohol or
drug withdrawal, infection, dehydration, discomfort) and consider pharmacologic agents only
if needed. SCCM guidelines provide a Grade C recommendation that “atypical antipsychotics
may reduce the duration of delirium in adult ICU patients.” No evidence exists on the efficacy
of haloperidol in reducing delirium and is associated with higher incidences of extrapyramidal
and cardiac side effects [38]. The atypical antipsychotics, which have been studied and shown
to be beneficial, are listed in Table 11. If such agents are initiated, it is crucial to ensure they
are discontinued upon discharge or follow‐up strategies are in place in the outpatient setting.
Patients should also be monitored carefully for the adverse effects listed.
The fundamental component of implementing successful protocols to manage pain, agitation,
and delirium in mechanically ventilated patients is a multidisciplinary team. Developing a
comprehensive protocol can help reduce costs, improve ICU outcomes, and create more
consistent practices. As presented earlier, the SCCM PAD Guideline concepts can be employed
but the basic principles established in cancer patients for managing pain and anxiety must also
be considered to achieve optimal outcomes.
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